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Abstract: The development of a new class of antibiotics to fight bacterial resistance is a
time-consuming effort associated with high-cost and commercial risks. Thus, modification,
conjugation or combination of existing antibiotics to enhance their efficacy is a suitable strategy.
We have previously reported that the amphiphilic cyclic peptide [R4 W4 ] had antibacterial activity
with a minimum inhibitory concentration (MIC) of 2.97 µg/mL against Methicillin-resistant
Staphylococcus aureus (MRSA). Herein, we hypothesized that conjugation or combination of the
amphiphilic cyclic peptide [R4 W4 ] with levofloxacin or levofloxacin-Q could improve the antibacterial
activity of levofloxacin and levofloxacin-Q. Fmoc/tBu solid-phase chemistry was employed to
synthesize conjugates of [R4 W4 K]-levofloxacin-Q and [R4 W4 K]-levofloxacin. The carboxylic acid
group of levofloxacin or levofloxacin-Q was conjugated with the amino group of β-alanine attached
to lysine in the presence of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU) and N,N-diisopropylethylamine (DIPEA) for 3 h to afford the products. Antibacterial
assays were conducted to determine the potency of conjugates [R4 W4 K]-levofloxacin-Q and
[R4 W4 K]-levofloxacin against MRSA and Klebsiella pneumoniae. Although levofloxacin-Q was
inactive even at a concentration of 128 µg/mL, [R4 W4 K]-levofloxacin-Q conjugate and the
corresponding physical mixture showed MIC values of 8 µg/mL and 32 µg/mL against MRSA
and Klebsiella pneumonia, respectively, possibly due to the activity of the peptide. On the other
hand, [R4 W4 K]-levofloxacin conjugate (MIC = 32 µg/mL and MIC = 128 µg/mL) and the physical
mixture (MIC = 8 µg/mL and 32 µg/mL) was less active than levofloxacin (MIC = 2 µg/mL
and 4 = µg/mL) against MRSA and Klebsiella pneumoniae, respectively. The data showed that the
conjugation of levofloxacin with [R4 W4 K] significantly reduced the antibacterial activity compared
to the parent analogs, while [R4 W4 K]-levofloxacin-Q conjugate was more significantly potent than
levofloxacin-Q alone.
Keywords: amphiphilic cyclic peptide; conjugation; combination; levofloxacin; levofloxacin-Q;
methicillin-resistant Staphylococcus aureus; Klebsiella pneumonia

1. Introduction
The discovery of penicillin [1,2] and streptomycin [3] and other antibiotics led to the treatment of
a number of prevalent microbial diseases. Resistance development emerged due to improper use and
limited the application of these gold standard antibiotics and generated an urgent need for exploration
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of new antibiotics [4,5]. The decline in the numbers of marketed antibiotics was mainly due to the
difficulty of compounds to penetrate bacterial cells [6] and high costs related to drug-development [7].
Modification, conjugation or combination of existing antibiotics to enhance the efficacy are among the
suitable strategies. Modification of known antibiotics has been used to improve absorption, distribution,
metabolism, and elimination (ADME) whereas conjugation of antibiotics with antibodies provides
targeted delivery and release of antibiotics to the site of action [8,9]. Similarly, combination approaches
have been applied to demonstrate improved antimicrobial therapy [10]. Furthermore, using two
antibiotics with synergistic activity simultaneously can reduce the required dosage and toxicity of each
compound. It has been previously shown that the combinational therapy broadens the antibacterial
spectrum and
lowers side effects. For example, a cationic antimicrobial peptide, arenicin-1,
was able
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Figure 1. Chemical structures of levofloxacin (1), levofloxacin-Q (2), and amphiphilic cyclic peptide [R4W4] (3).

Figure 1. Chemical structures of levofloxacin (1), levofloxacin-Q (2), and amphiphilic cyclic peptide [R4 W4 ] (3).
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To synthesize conjugates of 1 or 2, a lysine residue was incorporated into the cyclic peptide
To synthesize conjugates of 1 or 2, a lysine residue was incorporated into the cyclic peptide
followed by a short β-alanine linker. For the synthesis of conjugated peptides, Trp(Boc)-2-chlorotrityl
followed by a short β-alanine linker. For the synthesis of conjugated peptides, Trp(Boc)-2-chlorotrityl
resin was used as the solid-phase resin. Fmoc-Arg(Pbf)-OH, Fmoc-Trp(Boc)-OH, Fmoc-β-alanineresin was used as the solid-phase resin. Fmoc-Arg(Pbf)-OH, Fmoc-Trp(Boc)-OH, Fmoc-β-alanine-OH,
OH, and Fmoc-Lys(Dde)-OH were used as building block amino acids in the synthesis. The peptide
and Fmoc-Lys(Dde)-OH were used as building block amino acids in the synthesis. The peptide
sequence KRRRRWWWW was first assembled on solid-phase using Fmoc/tBu solid-phase
sequence KRRRRWWWW was first assembled on solid-phase using Fmoc/tBu solid-phase
methodology. Fmoc-β-alanine in the side chain of lysine was attached to Dde protected lysine at
methodology. Fmoc-β-alanine in the side chain of lysine was attached to Dde protected lysine at
N-terminal. After the deprotection of the Fmoc group of β-alanine, the free NH2 group was used for
N-terminal. After the deprotection of the Fmoc group of β-alanine, the free NH2 group was used
conjugation with levofloxacin or levofloxacin-Q using coupling and activating agents, HBTU and
for conjugation with levofloxacin or levofloxacin-Q using coupling and activating agents, HBTU
DIPEA, respectively. The conjugation was completed in 3 h by monitoring with MALDI mass
and DIPEA, respectively. The conjugation was completed in 3 h by monitoring with MALDI mass
spectroscopy. The N-terminal protection of the Dde group in the lysine was deprotected using 2%
spectroscopy. The N-terminal protection of the Dde group in the lysine was deprotected using 2%
hydrazine hydrate in N,N-dimethylformamide (DMF). The resin was divided into two sections.
hydrazine hydrate in N,N-dimethylformamide (DMF). The resin was divided into two sections.
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K] with
with levofloxacin
levofloxacin and
and levofloxacin-Q.
levofloxacin-Q.

The first section was used for the synthesis of linear peptide–drug conjugate. The linear peptide–
The first section was used for the synthesis of linear peptide–drug conjugate. The linear
drug conjugate was cleaved using freshly prepared cleavage cocktail of trifluoroacetic acid (TFA),
peptide–drug conjugate was cleaved using freshly prepared cleavage cocktail of trifluoroacetic acid
anisole, thioanisole, and dithiothreitol (DTT) followed by precipitation and purification.
(TFA), anisole, thioanisole, and dithiothreitol (DTT) followed by precipitation and purification.
The second part of the resin was used for the synthesis of cyclic peptide–drug conjugate. The cleavage
The second part of the resin was used for the synthesis of cyclic peptide–drug conjugate.
of the protected peptide from the resin was accomplished by using cleavage cocktail, dichloromethane,
The cleavage of the protected peptide from the resin was accomplished by using cleavage
trifluoroethanol, acetic acid (DCM:TFE:AcOH; 7:2:1 v/v/v) to generate the side-chain protected linear
cocktail, dichloromethane, trifluoroethanol, acetic acid (DCM:TFE:AcOH; 7:2:1 v/v/v) to generate
peptide. The N- to C-terminal cyclization was carried out using N,N′-diisopropylcarbodiimide (DIC),
the side-chain protected linear peptide. The N- to C-terminal cyclization was carried out using
1-hydroxy-7-azabenzotriazole
(HOAT) in the presence of DCM/DMF overnight. Once the peptide
N,N 0 -diisopropylcarbodiimide (DIC), 1-hydroxy-7-azabenzotriazole (HOAT) in the presence of
became cyclized as confirmed by MALDI, the crude peptide was cleaved using freshly prepared final
DCM/DMF overnight. Once the peptide became cyclized as confirmed by MALDI, the crude peptide
cleavage cocktail of TFA, anisole, thioanisole, and DTT followed by precipitation and purification.
was cleaved using freshly prepared final cleavage cocktail of TFA, anisole, thioanisole, and DTT
After final deprotection of the side chains, HPLC and MALDI were used for purification and
followed by precipitation and purification. After final deprotection of the side chains, HPLC and
characterization of the compounds, respectively. The physical mixtures of the peptides and drug
MALDI were used for purification and characterization of the compounds, respectively. The physical
were prepared in 1:1 molar ratio.
mixtures of the peptides and drug were prepared in 1:1 molar ratio.
2.2.
2.2. Antibacterial
Antibacterial Assay
Assay
MIC
for all
peptides were
measured
for activity
against
pneumoniae
MIC values
values
forfour
allconjugated
four conjugated
peptides
were
measured
forKlebsiella
activity
against
and
MRSA
bacterial
strains
(Table
1)
and
compared
with
physical
mixtures
of
levofloxacin
(1) +
Klebsiella pneumoniae and MRSA bacterial strains (Table 1) and compared with physical mixtures
[R4W4] (3) and levofloxacin-Q (2) + [R4W4] (3). Although levofloxacin-Q (2) was inactive even at a
concentration of 128 µg/mL, [R4W4]-levofloxacin-Q (9) and the corresponding physical mixture
showed MIC values of 8 µg/mL, possibly due to the activity of the peptide. On the other hand,
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of levofloxacin (1) + [R4 W4 ] (3) and levofloxacin-Q (2) + [R4 W4 ] (3). Although levofloxacin-Q (2) was
inactive even at a concentration of 128 µg/mL, [R4 W4 ]-levofloxacin-Q (9) and the corresponding
physical mixture showed MIC values of 8 µg/mL, possibly due to the activity of the peptide.
On the other hand, [R4 W4 K]-levofloxacin (8) (MIC = 32 µg/mL) and the physical mixture
levofloxacin + [R4 W4 ] (MIC = 8 µg/mL) were less active than levofloxacin (1) (MIC = 2 µg/mL).
The evaluation of antibacterial activity of [R4 W4 K]-levofloxacin (8) demonstrated that the
conjugation of levofloxacin (1) reduced the activity of the lead compound and did not show
synergistic activity. However, [R4 W4 K]-levofloxacin-Q (9) and levofloxacin-Q (2) + [R4 W4 ] (3) showed
higher antibacterial activity compared with levofloxacin-Q (2) that can be explained by the possible
antibacterial activity of 3. These data indicate that the presence of both the antibacterial peptide and
levofloxacin in [R4 W4 K]-levofloxacin (8) do not generate any synergistic antibacterial effect, possibly
due to the incomplete hydrolysis of [R4 W4 K]-levofloxacin to levofloxacin and [R4 W4 K(β-alanine)]
and masking the pharmacophore carboxylic acid group of levofloxacin in the conjugate. Reduced
antibacterial activity of the physical mixture by two-fold can be attributed to the dilution of [R4 W4 ]
after mixing with the levofloxacin in 1:1 molar ratio or physical interaction of the cyclic peptide
with levofloxacin.
Table 1. Antibacterial assay against Gram-positive and Gram-negative bacteria.
MIC (µg/mL) 1

Compounds

Meropenem
Vancomycin
Levofloxacin (1)
Levofloxacin-Q (2)
[R4 W4 ] (3)
Conjugate cyclic [R4 W4 ]-levofloxacin (8)
Conjugate linear (R4 W4 )-levofloxacin (6)
Levofloxacin (1) + [R4 W4 ] (3)
Levofloxacin-Q (2) + [R4 W4 ] (3)
Conjugate cyclic [R4 W4 ]-Levofloxacin-Q (9)
Conjugate linear (R4 W4 )-Levofloxacin-Q (7)
1

Methicillin-Resistant
Staphylococcus aureus (MRSA)

Klebsiella pneumoniae

N/A 2
1
2
>128
4
32
64
8
8
8
ND 3

1
N/A
4
>128
16
>128
>128
32
32
32
ND

MIC measurement reflects triplicate of three experiments; 2 N/A = not active; 3 ND = not determined.

3. Discussion
Our laboratory has previously reported that the amphiphilic cyclic peptide [R4 W4 ] (3),
a cell-penetrating peptide (CPP) (Figure 1) containing arginine (R) and tryptophan (W) residues has
antibacterial activity with MIC value of 2.97 µg/mL against MRSA, a multidrug-resistant bacterium
commonly found in the hospital and community settings [25]. Twenty-four-hour time-kill studies
that evaluated 3 in combination with tetracycline demonstrated bactericidal activity at 4–8 times the
MIC of tetracycline against MRSA (MIC = 0.5 µg/mL) and 2–8 times the MIC against Escherichia coli
(MIC = 2 µg/mL). This study suggested that amphiphilic cyclic CPPs with antibacterial activity can
be used in combination with tetracycline to provide a significant benefit against multidrug-resistant
pathogens when compared with the antibiotic treatment alone. The mechanism of cellular uptake
indicated that the intracellular transportation of amphiphilic cyclic peptide [R4 W4 ] (3) was controlled
by several mixed pathways [26]. Herein, we intend to see the effect of covalent conjugation or a physical
mixture of the peptide with another antibiotic, levofloxacin (1), against MRSA and Klebsiella pneumoniae.
Levofloxacin (1) is a well-known broad-spectrum antibiotic, which is active against both
Gram-positive and Gram-negative bacteria and is commonly is used for the treatment of several
types of infection in the clinical setting. It inhibits an important enzyme, topoisomerase, which
is required by the bacterial cell for DNA cell division. Levofloxacin-Q acid (2) is a derivative of
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levofloxacin which is inactive due to absence of piperazinyl moiety at C-7. These two compounds were
used in this study for covalent and physical mixture with the amphiliphic cyclic peptide [R4 W4 ] (3).
The attachment of (1) or (2) was achieved through a linker lysine-β-alanine to provide sufficient
space between the drug and cyclic peptide 3. The synthesis was designed to minimize the structural
changes. A lysine residue was incorporated into the sequence of the peptide containing four tryptophan
and four arginine residues. The cyclic amphiphilic peptide was synthesized using a minor modification
to our reported procedure [25] with the change of the resin to arginine(Pbf)-2-chlorotrityl resin.
The peptide was purified by HPLC and analyzed by using MALDI mass spectroscopy and used in the
antibacterial assay.
The synthesis of conjugates of 1 and 2 was accomplished through Fmoc/tBu solid-phase synthesis
(Scheme 1). The carboxylic acid functional group of 1 and 2 (Figure 1) was used for conjugation
with the amino group in the cyclic peptide. The conjugation strategy was carried out on the
solid-support for quick and fast access to the conjugated compound as compared to the solution-phase
chemistry that requires multiple protection/deprotection steps with tedious purification at each step.
To facilitate solid-phase synthesis, cyclic peptide synthesis was started using Trp(Boc)-2-chlorotrityl
resin followed by 3 coupling of Fmoc-Trp(Boc)-OH, 4 coupling of Fmoc-Arg(Pbf)-OH, one coupling
of Dde-Lys(Fmoc)-OH, and one coupling of Fmoc-β-alanine-OH to assemble the protected peptide
W(Boc)4 R(Pbf)4 K-β-alanine-NH2 on the solid support. Coupling was carried out in the presence of
HBTU and DIEPA in anhydrous DMF and deprotection was accomplished using 20% piperidine in
DMF. The conjugation of 1 or 2 was achieved using HBTU/DIPEA for 3 h after monitoring with
MALDI mass spectroscopy. The Dde group was removed to provide free N-terminal using 2%
hydrazine hydrate. The linear conjugated peptide of 1 or 2 was achieved after final cleavage of the
peptide from the side chain and resin using a cleavage cocktail followed by purification and analysis.
The cyclization was facilitated for cyclic levofloxacin or levofloxacin-Q conjugated peptides using a
cocktail, DCM:TFE:AcOH followed by cyclization overnight using DIC/HOAt in DCM:DMF. The cyclic
peptides were cleaved and deprotected followed by HPLC purification to afford conjugated peptides.
The antibacterial activity of linear or cyclic conjugated peptides of levofloxacin or levofloxacin-Q
were tested against MRSA and Klebsiella pneumoniae (Table 1). The bacterial strains were obtained
from our local community. Meropenem and vancomycin were used as control antibiotics along with
1 and 2 in the antibacterial assay. The physical mixture of levofloxacin (1) + [R4 W4 ] (3) was more
potent than the covalent conjugate of antibiotic and peptide, presumably because of the presence
of the free parent analogs. Furthermore, the physical mixture (Levofloxacin-Q + [R4 W4 ]) and or
covalent conjugation of levofloxacin-Q ([R4 W4 ]-Levofloxacin-Q) showed improved activity when
compared with levofloxacin-Q. Levofloxacin-Q alone showed antibacterial activity at a concentration
higher than 128 µg/mL against both MRSA and Klebsiella pneumoniae which was improved in the
physical mixture/covalent conjugation to 8 and 32 µg/mL against MRSA and Klebsiella, respectively.
However, the antibacterial activity of the physical mixture (1 + 3) or covalently conjugated compound
([R4 W4 ]-levofloxacin (8)) was reduced when compared to 1 or 3 alone. Similarly, the conjugate of
the linear peptide (R4 W4 -levofloxacin (6)/R4 W4 -levofloxacin-Q (7)) was also tested which showed
low antibacterial activity (MIC = 64 µg/mL) as compared to the cyclic peptide (3) and or levofloxacin
(1) alone. We assume that conjugation of levofloxacin (1) using the COOH group blocks the
pharmacophore group of the drug. The conjugated compound needs to be hydrolyzed to release
the drug-containing free COOH group. The amide linkage of the drug with the peptide possibly
does not hydrolyze fast in the assay conditions. The reduced antibacterial activity of the physical
mixture (1:1 molar ratio) is possibly due to the presence of less cyclic peptide or possible physical
interaction through electrostatic interactions of the cyclic peptide and levofloxacin or levofloxacin-Q.
It was well documented that the C-7 position in fluoroquinolones antibacterial agents associated with
their antibacterial spectrum, bioavailability, and safety [27–29]. The bulkier groups were found to
be more favored as compared to the smaller group (fluorine) on C-7 substituent [30,31]. Therefore,
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a fluoroquinolone with a C-7 substituent containing a piperazinyl ring with the N4 methyl group was
found to be more potent.
The discovery and development of novel antibiotics have been limited during the last few years.
The discovery of novel antibiotics is urgently required to treat antibiotic-resistant bacteria. One of
the emerging areas is using antibody–antibiotic conjugates (AAC), which have shown potential in
recent years against killing the resistant bacteria, such as MRSA [8]. However, due to the bulky nature
of the antibody and the associated immunogenic response by the body, this strategy will pose more
challenges as compared to the use of peptide–antibiotic conjugates (PAC). Thus, the conjugate of
the amphiphilic cyclic peptide [R4 W4 ] (3) with antibiotics can be an alternative strategy. However,
structural optimization is required to ensure that the conjugates dissociate in order to release the
antibiotic drug and cyclic peptide in such a way that they work synergistically. Another worthwhile
approach in this direction is to examine the combination of more conventional antibiotics with the
amphiphilic cyclic antibacterial peptide in combination strategies to exploit multiple mechanisms to
kill resistant bacteria.
4. Materials and Methods
4.1. General Methods
Protected L-amino acids and preloaded H-Trp(Boc)-2-chlorotrityl resin were purchased from
Aapptec LLC, Louisville, KY, USA. All the other chemicals and reagents, such as DIPEA, piperidine,
trifluoroacetic acid (TFA), DMF, and HPLC grade acetonitrile were purchased from Sigma-Aldrich
Co (Milwaukee, WI, USA). Levofloxacin (TCI America, Portland, OR, USA) and Levofloxacin
Q-acid were purchased from TCI America, USA. The chemical structures of final products were
confirmed by high-resolution MALDI-TOF (GT 0264) from Bruker Daltonics, Inc., San Jose,
CA, USA Final compounds were purified by a reversed-phase HPLC from Shimadzu Scientific
Instruments, Inc., Pleasanton, CA, USA (LC-20AP) using a gradient system of acetonitrile and
water using a reversed-phase preparative column (XBridge BEH130 Prep C18). Methicillin Resistant
Staphylococcus aureus (Los Angeles County (LAC) clone) was obtained from the Los Angeles Public
Health Department, CA, USA. Mueller Hinton media were purchased from Hardy Diagnostics, Lacey,
WA, USA.
4.2. Synthesis of Cyclic Peptide [R4 W4 ] (3)
The peptide was manually synthesized using a Chemglass peptide synthesis vessel (#CG1860)
with the help of bubbling anhydrous nitrogen gas as reported by us previously—with minor
modification. H-Arg(Pbf)-2-chlorotrityl resin (0.44 meq/g, 0.3 mmole, 681 mg) was added to the glass
vessel and DMF (50 mL, 30 min × 2) with the help of nitrogen gas to swell the resin. Fmoc-Arg(Pbf)-OH
(1.2 mmol, 778 mg) was coupled using HBTU (1.2 mmol, 455 mg), DIPEA (2.4 mmol, 1.0 mL) and
DMF (15 mL) for 2 h. The resin was washed with DMF (25 mL × 3) and followed by deprotection
of the Fmoc group using 20% piperidine in DMF (20 mL, 10 min × 2) with the washing of the
resin at the end. Two more couplings were performed using Fmoc-Arg(Pbf)-OH followed by four
successive couplings with Fmoc-Trp(Boc)-OH (1.2 mmol, 632 mg), HBTU (1.2 mmol, 455 mg),
DIPEA (2.4 mmol, 1.0 mL), and DMF (15 mL) for 2 h. At the end, the N-terminal Fmoc group
was deprotected followed by cleavage of the protected peptide from the resin by agitation with
a cleavage cocktail, dichloromethane, trifluoroethanol, acetic acid (TFE:AcOH:DCM; 1:2:7, v/v/v,
50 mL) for 3 h. The filtrate was evaporated, and hexane (2 × 20 mL) and DCM (2 ×15 mL) were
added to the residue to remove the acetic acid from the mixture. The crude material was solidified
as a white solid. The crude peptide was dried under vacuum overnight followed by the addition
of anhydrous DMF (200 mL), anhydrous DCM (50 mL), HOAt (1.2 mmol, 4 equiv, 136 mg) with
stirring and dropwise addition of DIC (1.32 mmol, 4.4 equiv, 207 µL) to the crude protected linear
peptide for cyclization. The reaction mixture was stirred under nitrogen overnight followed by MALDI
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analysis which confirmed complete cyclization. The solvents were removed under reduced pressure
followed by complete deprotection of the peptide by agitation with freshly prepared cleavage cocktail
reagent R using trifluoroacetic acid/anisole/1,2-ethanedithiol/thioanisole cocktail (90:2:3:5 (v/v/v/v),
20 mL) for 2 h at room temperature followed by centrifugation and precipitation to analyze the crude
peptide. The crude peptide was purified by a reversed-phase high-pressure liquid chromatography
(RP-HPLC) system with a gradient from 0 to 100% acetonitrile (CH3 CN) containing 0.1% (v/v) TFA
and water containing 0.1% (v/v) TFA for 1 h with a flow rate of 8.0 mL/min at a wavelength of 220 nm.
[R4 W4 ] (3): MALDI-TOF (m/z): C68 H88 N24 O8 : calcd., 1368.7217; found, 1369.4419 [M + H]+ .
4.3. Synthesis of Linear (R4 W4 K)-Levofloxacin (6) and (R4 W4 K)-Levofloxacin-Q (7) and Cyclic
[R4 W4 K]-Levofloxacin (8) and [R4 W4 K]-Q-Levofloxacin (9) Conjugates
First, the protected peptide W(Boc)4 R(Pbf)4 K-β-alanine-NH2 on the solid support was
synthesized using Fmoc-based solid-phase peptide synthesis (Fmoc-SPPS) as described earlier,
used for conjugation of levofloxacin and levofloxacin-Q acid. The synthesis was carried out using
NH2 -Trp(Boc)-2-chlorotrityl resin (loading, 0.3 mmol/g, 1 gm, 0.3 mmol) after swelling the resin
with agitation in DMF (100 mL, 30 min × 2) and bubbling anhydrous nitrogen gas. Coupling
and a deprotection cycle followed in order to assemble the peptide sequence on the solid support.
Coupling of amino acids was performed using 4 equiv. of amino acids (three times coupling of
Fmoc-Trp(Boc)-OH, four times coupling of Fmoc-Arg(Pbf)-OH, one coupling using Dde-Lys(Fmoc)-OH,
and one coupling using Fmoc-β-Ala-OH) in the presence of HBTU (4 equiv.) and DIPEA (8 equiv.)
in DMF (15 mL) as coupling and activating reagents, respectively, for 2 h. After every coupling, the
resin was washed with DMF (20 mL × 3) followed by deprotection of the Fmoc group using 20%
piperidine in DMF (v/v, 20 mL × 2, 10 min). The resin was washed with DMF (20 mL × 3). After the
synthesis of the protected peptide on the resin, W(Boc)4 R(Pbf)4 K-β-alanine-NH2 , the levofloxacin or
Q-levofloxacin (4 equiv.) were conjugated in the presence of HBTU (4 equiv.) and DIPEA (8 equiv.)
with agitation under nitrogen for 3 h. Small cleavage of the resin confirmed the formation of the
conjugated peptide. The Dde protecting group was removed using 2% hydrazine hydrate in DMF
(v/v, 30 mL, 10 min × 4) from the N-terminal of lysine to afford the free NH2 group. Half of the resin
was washed with DMF (15 mL, 2 × 5 min) and used for linear peptide–drug conjugate by complete
cleavage of peptidyl resin using a cleavage cocktail TFA, anisole, thioanisole, DDT (90:2:3:5, v/v/v,
20 mL) for 3 h followed by precipitation and centrifugation. The second half of the resin was used
for cyclization using cleavage of the protected peptide from the resin with agitation in a cocktail
(dichloromethane, trifluoroethanol, acetic acid (TFE:AcOH:DCM; 1:2:7, v/v/v, 50 mL)) for 3 h. The
filtrate was evaporated, and hexane (2 × 20 mL) and DCM (2 × 15 mL) were added to the residue
to remove the acetic acid from the mixture. The crude material was solidified as a white solid. The
crude peptide was dried under vacuum overnight. Anhydrous DMF (200 mL), anhydrous DCM
(50 mL), DIC (4.4 equiv.) and HOAt (4 equiv.) were added to the crude unprotected linear peptide
for cyclization. The reaction mixture was stirred under nitrogen overnight. After the formation of
the cyclic peptide was confirmed by MALDI analysis, the solvents were removed under reduced
pressure. The crude peptide was dried overnight. The final cleavage cocktail (TFA, anisole, thioanisole,
DTT, 90:2:3:5, v/v/v, 20 mL) was added to the crude product. The mixture was stirred at room
temperature for 5 h. The crude peptide was precipitated in cold diethyl ether and centrifuged, purified
by using reversed-phase HPLC, and lyophilized. The molecular mass of synthesized compounds are
as follows: Linear (R4 W4 K)-levofloxacin (6): MALDI-TOF (m/z): C95 H125 FN30 O14 : calcd., 1928.9976;
found, 1929.7300 [M + H]+ , 1930.7400 [M + 2H]+ ; Linear (R4 W4 K)-levofloxacin-Q (7): MALDI-TOF
(m/z): C90 H114 F2 N30 O14 : calcd., 1848.9037; found, 1871.6920 [M + Na]+ , 1889.6823 [M + K]+ ; cyclic
[R4 W4 K]-levofloxacin (8): MALDI-TOF (m/z): C95 H123 FN30 O13 : calcd., 1910.9870; found, 1912.7700
[M + 2H]+ ; cyclic [R4 W4 K]-levofloxacin-Q (9): MALDI-TOF (m/z): C90 H112 F2 N30 O13 : calcd., 1830.8932;
found, 1832.4802 [M + 2H]+ .
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4.4. Antibacterial Assay
The antibacterial activities of synthesized peptides were evaluated against two bacterial strains
and compared to a control antibiotic and [R4 W4 ]. Gram-negative bacteria: Klebsiella pneumoniae
(Clinical strain (levofloxacin-susceptible)) and the Gram-positive bacteria: Methicillin-Resistant
Staphylococcus aureus (Los Angeles County (LAC) clone) were employed for the determination of
antimicrobial activities of peptides. MRSA and Klebsiella pneumoniae were inoculated into 5 mL of
Mueller Hinton agar (MH) at 37 ◦ C and shaken in an orbital shaker at 175 rpm overnight. The cultured
suspension was diluted in 5 mL normal saline until it achieved 0.5 McFarland (1.5 × 108 bacterial
cell density) turbidity. An amount of 40 µL of the McFarland solution was added to 5980 µL of MH
media to make 1/150 dilution. Most peptides were dissolved in distilled water (except some of them
that were dissolved in 50 mM NH4 HCO3 to improve the solubility) to make 256 µg/mL solutions.
Minimal inhibitory concentrations (MICs) were determined using the broth microdilution method.
Briefly, 200 µL of all tested peptides and controls was added in the first column of the 96-well plate.
Then, by adding 100 µL of media to the other wells and performing a 2-fold dilution in each well, serial
dilution of the compound was prepared. After a series of 2-fold dilutions, 100 µL of bacterial solution
was added to all wells, and then the microliter plates were incubated statically at 37 ◦ C overnight.
MICs were determined as the minimal concentration at which no visible bacterial growth was present.
All experiments were conducted in triplicate.
5. Conclusions
In this study, we attempted to improve the antibacterial activity of levofloxacin by conjugating
to [R4 W4 ] (3), a cationic antibacterial peptide. The parent peptides and the final conjugates were
successfully synthesized by Fmoc-SPPS, purified by HPLC, and characterized by MALDI. The physical
mixture of [R4 W4 ] (3) and levofloxacin-Q (2) (an inactive drug) and the conjugation showed improved
antibacterial activity in comparison to the parent analog alone. On the other hand, the conjugation
diminished the activity of 1, while the corresponding physical mixture just reduced the activity. Further
studies are required to explore antimicrobial peptides with synergistic activity with other antibiotics.
These data provided insights into designing antibacterial-peptide-antibiotics and combinations to
improve antimicrobial activity.
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